Relay Therapeutics (RLAY) insider plans sale of 30,000 shares after option exercise

Rhea-AI Filing Summary

Relay Therapeutics insider Sekar Kathiresan filed a notice to sell company stock. The filing covers a proposed sale of 30,000 shares of common stock of Relay Therapeutics through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate value of $594,414.00, expected on July 21, 2026. The shares are tied to a stock option exercise by the issuer for cash. The filing also reports that, during the past three months, 66,055 shares of common stock were sold on July 20, 2026 for total proceeds of $1,293,555.07.

Key Figures

Proposed shares to be sold: 30,000 shares Aggregate value of proposed sale: $594,414.00 Shares sold during past 3 months: 66,055 shares +2 more

5 metrics

Proposed shares to be sold 30,000 shares Common stock proposed for sale on July 21, 2026

Aggregate value of proposed sale $594,414.00 Total value of 30,000 common shares to be sold

Shares sold during past 3 months 66,055 shares Common stock sold on July 20, 2026

Proceeds from past 3 months sale $1,293,555.07 Total proceeds from 66,055 shares sold on July 20, 2026

Market NASDAQ Listing market for the common stock

Key Terms

stock option exercise, Executive Financial Services, Form 144

3 terms

stock option exercise financial

"Common | 07/21/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

Executive Financial Services financial

"Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/21/2026 - 04:11 PM Accepted by SEC EDGAR 07/21/2026 - 04:10 PM Learn about SEC filing dates

FAQ

What stock sale is disclosed for Relay Therapeutics (RLAY) in this Form 144?

The notice covers a proposed sale of 30,000 shares of Relay Therapeutics common stock, with an aggregate value of $594,414.00, expected to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on July 21, 2026.

Who is the selling security holder in the Relay Therapeutics (RLAY) Form 144 filing?

The selling security holder is Sekar Kathiresan, associated with an address at 60 Hampshire Street, Cambridge, MA 02139, who is reporting a proposed sale of 30,000 shares of Relay Therapeutics common stock linked to a stock option exercise.

How many Relay Therapeutics (RLAY) shares were sold in the past three months?

The filing states that 66,055 shares of Relay Therapeutics common stock were sold on July 20, 2026, generating total proceeds of $1,293,555.07, and this activity is disclosed as securities sold during the past three months.

What is the nature of the planned Relay Therapeutics (RLAY) share sale?

The planned transaction involves common stock issuable in connection with a stock option exercise by the issuer, with 30,000 shares expected to be sold for cash on July 21, 2026 through Morgan Stanley Smith Barney LLC Executive Financial Services.

On which market are the Relay Therapeutics (RLAY) shares in this Form 144 listed?

The common shares referenced in the filing are listed on the NASDAQ market. The proposed sale of 30,000 shares with an aggregate value of $594,414.00 is described in connection with this listing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	30000	594414.00	191586165	07/21/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/21/2026	Stock Option Exercise	Issuer			30000	07/21/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
SEKAR KATHIRESAN 60 Hampshire Street Cambridge MA 02139	Common	07/20/2026	66055	1293555.07

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)